This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2022 Apr 1;26(4):379-380.

doi: 10.5588/ijtld.22.0037.

After DOT, the brave new world?

J Noeske¹, C Kuaban²

Affiliations

PMID: 35351247
DOI: 10.5588/ijtld.22.0037

Comment

After DOT, the brave new world?

J Noeske et al. Int J Tuberc Lung Dis. 2022.

. 2022 Apr 1;26(4):379-380.

doi: 10.5588/ijtld.22.0037.

Authors

J Noeske¹, C Kuaban²

Affiliations

¹ Independent Consultant, Yaounde, Cameroon.
² Faculty of Health Sciences, University of Bamenda, Bambili, Cameroon.

PMID: 35351247
DOI: 10.5588/ijtld.22.0037

No abstract available

PubMed Disclaimer

Comment in

Digital medication adherence technology: towards personalised TB care.
van Boven JFM, Alffenaar JC. van Boven JFM, et al. Int J Tuberc Lung Dis. 2022 Apr 1;26(4):380-381. doi: 10.5588/ijtld.22.0067. Int J Tuberc Lung Dis. 2022. PMID: 35351248 No abstract available.

Comment on

An Inca trail to the Holy Grail: digital medication adherence support for TB care.
van Boven JFM, Alffenaar JC. van Boven JFM, et al. Int J Tuberc Lung Dis. 2022 Jan 1;26(1):1-3. doi: 10.5588/ijtld.21.0613. Int J Tuberc Lung Dis. 2022. PMID: 34969420 No abstract available.

Publication types

Actions

MeSH terms

Actions
Actions

LinkOut - more resources

Full Text Sources
- Ingenta plc